Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.
Lineage Cell Therapeutics, Inc. (Symbol: LCTX) is a clinical-stage biotechnology company that is pioneering the development and commercialization of novel therapies designed to address degenerative diseases. With a foundation built on pluripotent cell technology, Lineage Cell's innovative approach leverages cells capable of transforming into any type of cell in the human body. This groundbreaking capability allows for therapies aimed at regenerating or replacing damaged cells and tissues, providing hope for conditions that currently have no cure.
The company's pipeline is robust and diverse, encompassing several key product candidates:
- OpRegen: A retinal pigment epithelium transplant therapy targeting dry age-related macular degeneration, a leading cause of vision loss among the elderly.
- OPC1: An oligodendrocyte progenitor cell therapy designed to treat acute spinal cord injuries by promoting cell replacement and recovery.
- VAC2: An allogeneic cancer immunotherapy utilizing antigen-presenting dendritic cells to fight non-small cell lung cancer.
- ANP1: A promising therapy involving the transplant of allogeneic auditory neuron progenitor cells to combat hearing loss.
- PNC1: An innovative approach using allogeneic photoreceptor cell transplants aimed at treating vision loss.
Lineage Cell Therapeutics is committed to addressing large unmet medical needs through its cutting-edge technologies. The company's clinical-stage programs are supported by a premier collection of pluripotent cell assets, positioning it at the forefront of regenerative medicine.
Recent achievements include significant progress in clinical trials, strategic partnerships, and advancements in their product development pipeline. Financially, the company remains poised for growth with a clear focus on expanding its therapeutic offerings and enhancing shareholder value.
Stay informed with the latest updates and developments at Lineage Cell Therapeutics as they continue to advance their mission of transforming the treatment landscape for degenerative diseases.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotech firm, has been added to the Russell 3000® Index, effective July 1, 2024. This inclusion is part of FTSE Russell's annual reconstitution, which ranks the 4,000 largest US stocks by market cap. Membership in the Russell 3000® Index means automatic inclusion in either the Russell 1000® or Russell 2000® Index, as well as growth and value style indexes.
Brian M. Culley, CEO of Lineage, expressed optimism, noting that the inclusion could heighten investor awareness, boost institutional ownership, and provide additional liquidity for their stock. The Russell US indexes serve as benchmarks for $10.5 trillion in assets. FTSE Russell CEO Fiona Bassett highlighted the indexes' role in reflecting the dynamic US economy.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company, announced that CEO Brian M. Culley will present at the 2024 BIO International Convention on June 4, 2024, at 2:30 pm in Theater 3.
The company will also engage in meetings with potential partners to explore strategic alliances for its cell therapy transplant programs.
The BIO International Convention, the world's largest biotech industry gathering, will take place from June 3-6, 2024, at the San Diego Convention Center.
Lineage Cell Therapeutics has announced updates to the 2nd Annual Spinal Cord Injury Investor Symposium (SCIIS), scheduled for June 26-27, 2024, in San Diego. The event aims to enhance SCI research and treatment by bringing together companies, regulators, patients, and investors. The symposium will feature expanded sessions including clinical discussions with Neuralink and preclinical insights from Axonis, Novoron, Sania, and Rewire Medical. Key speakers include experts from RUSH University, the Miami Project to Cure Paralysis, and the Christopher & Dana Reeve Foundation, among others. The event seeks to foster collaboration, raise awareness, and attract investment in SCI treatment development.
Lineage Cell Therapeutics, Inc. reported its first quarter 2024 financial results, revealing significant milestones and data updates on the OpRegen program. The company established a new services agreement with Genentech to support ongoing development and presented positive clinical data at industry events. Additionally, Lineage announced the initiation of the OPC1 clinical study for spinal cord injuries and received a grant from CIRM. The appointment of Dr. Charlotte Hubbert as VP of Corporate Development and a strong balance sheet with $43.6 million in cash, cash equivalents, and marketable securities highlight the company's progress and potential.
Lineage Cell Therapeutics, Inc. presented 24-month visual acuity results of OpRegen (RG6501) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at the 2024 Retinal Cell & Gene Therapy Innovation Summit. The data showed BCVA gains of +5.5 letters at 24 months in Cohort 4 patients, with additional gains observed in patients with extensive OpRegen bleb coverage. The study suggested that OpRegen may counteract RPE cell dysfunction and loss in GA by supporting remaining retinal cells, with effects lasting at least 2 years post-administration.
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) will announce its first quarter 2024 financial results on May 9, 2024. The company, focused on developing allogeneic cell therapies, will host a conference call to discuss the results and provide a business update.
Lineage Cell Therapeutics, Inc. (LCTX) received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM) to support the 2nd Annual Spinal Cord Injury Investor Symposium. The symposium aims to accelerate development in spinal cord injury research and treatments by bringing together stakeholders in the field. It will focus on discussing current and future treatment alternatives, raising investor awareness, and broadening investment into spinal cord injury. The event will feature speakers from various organizations and will take place on June 26 and 27, 2024, in La Jolla, CA.
Lineage Cell Therapeutics, Inc. announces the passing of its Chairman, Mr. Alfred D. Kingsley, and appoints Michael H. Mulroy, J.D., as the new Chairman of the Board of Directors. Mr. Kingsley's significant contributions to the company are acknowledged, and Mr. Mulroy brings extensive experience in biotech and biopharma to his new role.
FAQ
What does Lineage Cell Therapeutics, Inc. specialize in?
What are the main product candidates of Lineage Cell Therapeutics?
What is OpRegen?
How does Lineage Cell Therapeutics utilize pluripotent cells?
What is OPC1 designed to treat?
What type of cancer is VAC2 targeting?
What recent achievements has Lineage Cell Therapeutics made?
What is ANP1?
What is the financial outlook of Lineage Cell Therapeutics?
Where can I find the latest updates on Lineage Cell Therapeutics?
